NCT06053801View on ClinicalTrials.gov

A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China

CompletedOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

August 10, 2025

Study Completion Date

August 10, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
OTHER

Xolair

Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.

Trial Locations (10)

116000

Novartis Investigative Site, Dalian

200072

Novartis Investigative Site, Shanghai

200443

Novartis Investigative Site, Shanghai

226000

Novartis Investigative Site, Nantong

310001

Novartis Investigative Site, Hangzhou

310006

Novartis Investigative Site, Hangzhou

325000

Novartis Investigative Site, Wenzhou

350025

Novartis Investigative Site, Fuzhou

410008

Novartis Investigative Site, Changsha

510091

Novartis Investigative Site, Guangdong

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY